![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RAC2 |
Gene summary for RAC2 |
![]() |
Gene information | Species | Human | Gene symbol | RAC2 | Gene ID | 5880 |
Gene name | Rac family small GTPase 2 | |
Gene Alias | EN-7 | |
Cytomap | 22q13.1 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A024R1P2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5880 | RAC2 | N_HPV_2 | Human | Cervix | N_HPV | 9.37e-10 | -2.58e-02 | -0.0131 |
5880 | RAC2 | CCI_1 | Human | Cervix | CC | 5.31e-06 | -7.09e-01 | 0.528 |
5880 | RAC2 | CCI_2 | Human | Cervix | CC | 2.93e-05 | -7.06e-01 | 0.5249 |
5880 | RAC2 | CCI_3 | Human | Cervix | CC | 5.15e-09 | -7.18e-01 | 0.516 |
5880 | RAC2 | CCII_1 | Human | Cervix | CC | 8.43e-15 | -7.38e-01 | 0.3249 |
5880 | RAC2 | Tumor | Human | Cervix | CC | 1.63e-18 | -5.17e-01 | 0.1241 |
5880 | RAC2 | sample1 | Human | Cervix | CC | 1.39e-08 | -6.82e-01 | 0.0959 |
5880 | RAC2 | sample3 | Human | Cervix | CC | 9.02e-15 | -4.03e-01 | 0.1387 |
5880 | RAC2 | H2 | Human | Cervix | HSIL_HPV | 3.13e-20 | -6.73e-01 | 0.0632 |
5880 | RAC2 | L1 | Human | Cervix | CC | 1.17e-08 | -5.55e-01 | 0.0802 |
5880 | RAC2 | T1 | Human | Cervix | CC | 3.44e-13 | -6.03e-01 | 0.0918 |
5880 | RAC2 | T2 | Human | Cervix | CC | 2.35e-05 | -7.08e-01 | 0.0709 |
5880 | RAC2 | T3 | Human | Cervix | CC | 4.99e-17 | -4.19e-01 | 0.1389 |
5880 | RAC2 | LZE2T | Human | Esophagus | ESCC | 1.81e-03 | 7.62e-01 | 0.082 |
5880 | RAC2 | LZE4T | Human | Esophagus | ESCC | 2.87e-21 | 8.98e-01 | 0.0811 |
5880 | RAC2 | LZE7T | Human | Esophagus | ESCC | 7.05e-14 | 1.30e+00 | 0.0667 |
5880 | RAC2 | LZE8T | Human | Esophagus | ESCC | 1.83e-10 | 7.19e-01 | 0.067 |
5880 | RAC2 | LZE24T | Human | Esophagus | ESCC | 1.15e-11 | 5.17e-01 | 0.0596 |
5880 | RAC2 | LZE6T | Human | Esophagus | ESCC | 6.79e-38 | 2.10e+00 | 0.0845 |
5880 | RAC2 | P2T-E | Human | Esophagus | ESCC | 9.42e-19 | 3.60e-01 | 0.1177 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00329444 | Cervix | CC | regulation of mononuclear cell proliferation | 51/2311 | 227/18723 | 1.36e-05 | 2.73e-04 | 51 |
GO:00705859 | Cervix | CC | protein localization to mitochondrion | 33/2311 | 125/18723 | 1.46e-05 | 2.90e-04 | 33 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:00083608 | Cervix | CC | regulation of cell shape | 38/2311 | 154/18723 | 1.86e-05 | 3.46e-04 | 38 |
GO:19902666 | Cervix | CC | neutrophil migration | 32/2311 | 122/18723 | 2.25e-05 | 4.00e-04 | 32 |
GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
GO:00706617 | Cervix | CC | leukocyte proliferation | 65/2311 | 318/18723 | 2.56e-05 | 4.32e-04 | 65 |
GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
GO:00726559 | Cervix | CC | establishment of protein localization to mitochondrion | 31/2311 | 120/18723 | 4.13e-05 | 6.36e-04 | 31 |
GO:00026906 | Cervix | CC | positive regulation of leukocyte chemotaxis | 26/2311 | 94/18723 | 4.85e-05 | 7.34e-04 | 26 |
GO:00466516 | Cervix | CC | lymphocyte proliferation | 59/2311 | 288/18723 | 5.53e-05 | 8.10e-04 | 59 |
GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
GO:00457306 | Cervix | CC | respiratory burst | 14/2311 | 37/18723 | 6.97e-05 | 9.81e-04 | 14 |
GO:19027457 | Cervix | CC | positive regulation of lamellipodium organization | 14/2311 | 37/18723 | 6.97e-05 | 9.81e-04 | 14 |
GO:00329435 | Cervix | CC | mononuclear cell proliferation | 59/2311 | 291/18723 | 7.51e-05 | 1.03e-03 | 59 |
GO:00509213 | Cervix | CC | positive regulation of chemotaxis | 34/2311 | 141/18723 | 8.19e-05 | 1.11e-03 | 34 |
GO:00308657 | Cervix | CC | cortical cytoskeleton organization | 19/2311 | 61/18723 | 8.72e-05 | 1.16e-03 | 19 |
GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
GO:00716247 | Cervix | CC | positive regulation of granulocyte chemotaxis | 11/2311 | 27/18723 | 1.94e-04 | 2.24e-03 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541620 | Cervix | CC | Viral myocarditis | 27/1267 | 60/8465 | 2.43e-08 | 3.57e-07 | 2.11e-07 | 27 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0466612 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0521010 | Cervix | CC | Colorectal cancer | 27/1267 | 86/8465 | 8.60e-05 | 5.57e-04 | 3.30e-04 | 27 |
hsa052128 | Cervix | CC | Pancreatic cancer | 24/1267 | 76/8465 | 1.89e-04 | 1.11e-03 | 6.55e-04 | 24 |
hsa04664 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAC2 | SNV | Missense_Mutation | novel | c.266C>G | p.Ser89Cys | p.S89C | P15153 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
RAC2 | SNV | Missense_Mutation | novel | c.419N>A | p.Pro140Gln | p.P140Q | P15153 | protein_coding | tolerated_low_confidence(0.38) | benign(0.01) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
RAC2 | SNV | Missense_Mutation | c.486N>C | p.Gln162His | p.Q162H | P15153 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.606) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
RAC2 | SNV | Missense_Mutation | rs758461304 | c.562G>A | p.Ala188Thr | p.A188T | P15153 | protein_coding | tolerated_low_confidence(0.09) | benign(0.011) | TCGA-CM-4747-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | fluorouracil | SD |
RAC2 | SNV | Missense_Mutation | c.197N>A | p.Arg66His | p.R66H | P15153 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.976) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
RAC2 | SNV | Missense_Mutation | c.304C>T | p.Arg102Trp | p.R102W | P15153 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.925) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RAC2 | SNV | Missense_Mutation | novel | c.381N>T | p.Glu127Asp | p.E127D | P15153 | protein_coding | tolerated_low_confidence(0.11) | benign(0.005) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RAC2 | SNV | Missense_Mutation | novel | c.353N>G | p.Asp118Gly | p.D118G | P15153 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAC2 | SNV | Missense_Mutation | novel | c.296N>T | p.Pro99Leu | p.P99L | P15153 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.763) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAC2 | SNV | Missense_Mutation | novel | c.186G>T | p.Glu62Asp | p.E62D | P15153 | protein_coding | deleterious_low_confidence(0.04) | benign(0.102) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5880 | RAC2 | NA | idarubicin | IDARUBICIN | 28485375 | |
5880 | RAC2 | NA | doxorubicin | DOXORUBICIN | 21048526 |
Page: 1 |